

1. Record Nr.	UNINA9910616204703321
Titolo	Nuclear oncology : from pathophysiology to clinical applications // Duccio Volterrani [and four others], editors
Pubbl/distr/stampa	Cham, Switzerland : , : Springer, , [2022] ©2022
ISBN	3-031-05494-6
Edizione	[Third edition.]
Descrizione fisica	1 online resource (2241 pages)
Disciplina	616.99407575
Soggetti	Cancer - Radionuclide imaging Cancer - Radiotherapy Nuclear medicine
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Intro -- Preface to the Third Edition -- Preface to the Second Edition -- Preface to the First Edition -- Acknowledgments -- Contents -- About the Editors -- Contributors -- Part I: Basic Science -- 1 Cancer Biology of Molecular Imaging -- Introduction -- The Evolving Context of Molecular Imaging: Cancer Genomics and Epigenomics -- Hallmarks of Cancer -- The Tumor Mass -- Imaging the Tumor Mass -- Neovasculature -- Hypoxia -- Cellular Constituents and Cell-Cell Synergism of the Tumor Mass -- Immune Cell Cancer Immunotherapy -- Immune Checkpoint Blockade -- Imaging the Immune T Cells -- The Metastatic Process -- Imaging the Cancer Cell -- Total Lesion Glycolysis (TLG) as a Predictive Marker of Prognosis and Tumor Responsiveness -- Proliferation Imaging -- 18F-FLT Imaging of Proliferation After Chemotherapy -- The Cancer Biology of Cellular Lineage Plasticity and the Nuclear Imaging Phenotype -- Lineage Plasticity and Relevance to Molecular Imaging in Prostate Cancer -- Molecular Imaging of Fibroblast-Activating Protein, a Molecule Expressed in Tumor Stroma -- Oncogene and Non-oncogene Addiction -- Examples of Imaging the Action Driver Mutations in Cancer Cells Indirectly Through the Effects on Metabolism -- BRAF Inhibition in Advanced Melanoma with V600E Mutation -- Inhibition of MEK, a Downstream Signal Transduction Molecule in the RAS/BRAF/ERK

Pathway, Can Reverse 131I Resistance in Patie... -- Future Applications
-- References -- 2 Principles of Molecular Targeting for Radionuclide
Therapy -- Introduction -- The Choice of Radionuclide -- Nuclear
Properties -- Radioisotope Production -- Theranostics -- Instrument
Resolution and Biological Resolution -- Radiobiological Properties
Affecting the Choice of Radionuclide -- Radiation Microdosimetry and
Particle Range -- The Choice of a Chemical Platform -- Salts and
Covalent Bonds -- Chelating Agents.
Coordination of Tc(V) and Re(V) -- Nanoparticles -- Location of the
Target: The Challenges of Designing Radiotracers for Intracellular
Compartments -- Critical Subcellular Sites of Interaction with Ionizing
Radiation (Direct Effects) -- Radiation-Induced Biological Bystander
Effects (RIBBEs) -- Critical Subcellular Sites of Interaction with Ionizing
Radiation (Indirect Effects) -- Cell Membrane -- Mitochondria --
Transfectant Mosaic Spheroid Model -- Transfectant Mosaic Xenograft
Model -- Media Transfer -- LET and Dose Rate -- Conclusion --
References -- 3 Single-Photon Emitting Radiopharmaceuticals for
Diagnostic Applications -- Introduction -- 99mTc-Labeled
Radiopharmaceuticals -- 99mTc-Sodium Pertechnetate -- 99mTc-
Diphosphonates -- 99mTc-Radiocolloids -- 99mTc-Magroaggregated
Albumin -- 99mTc-Sestamibi -- 99mTc-Tetrofosmin -- 99mTc-
EDDA/HYNIC-Octreotide or Octreotate -- Lung Ventilation
Radiopharmaceuticals -- 99mTc-DTPA -- 99mTc-Techneas --
Xenon-133 -- Xenon-127 -- Radioiodinated Agents -- Sodium Iodide
-- Radioiodinated Metaiodobenzylguanidine -- 201Tl-Chloride --
111In-Pentetreotide -- 111In-Capromab Pentetide -- 67Ga-Citrate --
Suggested Readings -- 4 Positron-Emitting Radiopharmaceuticals for
Diagnostic Applications in Oncology -- Introduction -- Positron-
Emitting Radionuclides -- Carbon-11 (11C) -- Nitrogen-13 (13N) --
Oxygen-15 (15O) -- Fluorine-18 (18F) -- Copper-64 (64Cu) --
Gallium-68 (68Ga) -- Rubidium-82 (82Rb) -- PET
Radiopharmaceuticals -- Deoxy-[18F]fluoro-d-glucose -- Nitrogen-13
Ammonia -- Oxygen-15 Water -- Rubidium-82 Chloride -- [11C]
Methionine and Other Tracers for Protein Synthesis -- Choline-Based
Tracers for Phospholipid Synthesis -- Fluorine-18 Fluciclovine --
Gallium-68 PSMA Ligands -- Fluorine-18 Sodium Fluoride -- Fluorine-
18 Misonidazole and Other Hypoxia Tracers.
Fluorine-18 Fluorothymidine and Other Substrates for DNA Synthesis
-- Fluorine-18 DOPA and Other Amine Precursors -- Gallium-68
DOTATOC, Copper-64 DOTATATE, and Other Somatostatin Analogs --
Suggested Readings -- 5 Radiopharmaceuticals for Therapy --
Background -- Alpha-Particle Emitters -- Radium-223 (223Ra) --
Auger Electron Emitters -- Emitters of - Particles -- Iodine-131 (131I)
-- Yttrium-90 (90Y) -- Lutetium-177 (177Lu) -- Samarium-153
(153Sm) -- Strontium-89 (89Sr) -- Rhenium-186 (186Re) and
Rhenium-188 (188Re) -- Phosphorus-32 (32P) -- Holmium-166
(166Ho) -- Treatment of Thyroid Disease with 131I-Iodide --
Treatment of Neuroendocrine Neoplasms Originating from the Neural
Crest with [131I]MIBG -- Peptide Receptor Radionuclide Therapy --
Bone-Seeking Radiopharmaceuticals and Prostate Cancer --
Radioimmunotherapy for Hematologic Malignancies -- Radionuclide
Therapy of Primary and Metastatic Liver Tumors -- Suggested Readings
-- 6 Novel Single-Photon-Emitting Radiopharmaceuticals for
Diagnostic Applications -- Introduction and Background -- Peptide
Receptor Targeting -- 99mTc-EDDA/HYNIC-TOC -- 99mTc-PSMA-
Ligands -- 99mTc-CAIX -- Apoptosis -- 99mTc-Annexin V -- 99mTc-
Duramycin -- Angiogenesis -- 99mTc-HYNIC-VEGF -- Integrins --
99mTc-P2 -- 99mTc-NC100692 (or 99mTc-Maraciclalide) --

99mTc-3PRGD2 -- 99mTc-RGD-BBN -- Hybrid
Radioactive/Fluorescent RGD -- Agents Targeting the Extracellular Matrix -- 99mTc-AP39 -- Matrix Metalloproteinases -- Epidermal Growth Factor Receptor (EGFR) -- 99mTc-ADAPT6 -- Folate Receptor Overexpression -- 99mTc-HYNIC-folate -- References -- 7 Novel Positron-Emitting Radiopharmaceuticals -- Introduction -- Targeting Cellular Transport and Metabolism -- Overview -- Imaging Amino Acid Transport and Metabolism -- [11C]Methionine -- O-(2-[18F]Fluoroethyl)-L-Tyrosine ([18F]FET).
3,4-Dihydroxy-6-[18F]Fluorophenylalanine ([18F]FDOPA) -- 18F-Labeled Glutamine -- Imaging Lipid Biosynthesis -- Targeting Cell Surface Receptors -- Overview -- Imaging the Expression of Integrins -- Imaging the Expression of Gastrin-Releasing Peptide Receptors -- ImmunoPET Imaging -- ImmunoPET of HER2 -- ImmunoPET of EGFR -- ImmunoPET of PD-1/PD-L1 -- Targeting the Tumor Microenvironment -- Overview -- Imaging Tumor Hypoxia -- Imaging Tumor Acidosis -- Radiotheranostics -- Overview -- Targeting Somatostatin Receptors -- Targeting Prostate-Specific Membrane Antigen -- Radioimmunotherapy -- Concluding Remarks -- References -- 8 Novel Radiopharmaceuticals for Therapy -- Introduction -- Alpha-Emitting Agents -- Radium-223 (223Ra) -- Astatine-211 (211At) -- Actinium-225 (225Ac) -- Thorium-227 (227Th) -- Bismuth-213 (213Bi) -- Lead-212 (212Pb) -- Agents Emitting - Particles -- Iodine-131 (131I) -- Lutetium-177 (177Lu) -- Holmium-166 (166Ho) -- Ytterbium-175 (175Yb) -- Samarium-153 (153Sm) -- Thulium-170 (170Tm) -- Copper-67 (67Cu) -- Yttrium-90 (90Y) -- Gold-198 (198Au) -- Promethium-149 (149Pm) -- Rhodium-105 (105Rh) -- Other Radionuclides -- Concluding Remarks -- References -- 9 Physics of Nuclear Oncology -- Structure of the Atom -- Energy and Mass -- Energy and Frequency -- Energy and Mass -- Radioactivity and Radiation -- Electromagnetic Radiation -- X-Rays -- Gamma Radiation (γ) -- Annihilation Radiation (\pm) -- Particulate Radiations -- Alpha Radiation (α) -- Beta Radiation (β^-) -- Dosimetry -- Positron Decay (β^+) and Electron Capture (EC) -- Auger Electrons -- Isomeric Transition (IT) and Internal Conversion (IC) -- Radioactive Decay -- Interaction of Radiation with Matter -- Interaction of Particulate Radiation with Matter -- Interaction of Photons with Matter -- Photoelectric Effect -- Compton Scattering -- Pair Production.
Attenuation and Scattering of Photons -- Photon Attenuation -- Radionuclides Used in Nuclear Oncology -- References -- 10 Instrumentation for Positron Emission Tomography -- Introduction -- Basic Physics and Technology of PET -- Scintillation Crystals -- Silicon Photomultiplier (SiPM)-Based Scintillation Detectors -- Time-of-Flight (TOF) PET -- Total-Body PET -- PET/MRI -- Concluding Remarks -- References -- 11 Instrumentation for Single-Photon Emission Computed Tomography (SPECT) -- Introduction -- Radiation Detectors for SPECT -- Radionuclides for SPECT -- Gamma Camera Design -- SPECT Data-Acquisition -- Data ``Corrections`` and Activity Quantitation -- Image Reconstruction -- Commercial Devices -- Concluding Remarks -- References -- 12 Instrumentation for Intraoperative Detection and Imaging -- Introduction -- Nuclear Counting and Imaging -- Optical and Near-Infrared (NIR) Imaging -- Cerenkov Imaging -- Photoacoustic Imaging -- Diffuse Optical Tomography -- Optical Coherence Tomography -- Raman Spectroscopic Imaging -- Intraoperative US, CT, and MRI -- Concluding Remarks -- References -- 13 Radiobiology and Radiation Dosimetry in Nuclear Medicine -- Introduction -- Radiobiology -- Conventional Radiobiological Models -- Cell Death Mechanisms -- Possible

Contributing Mechanisms to RNT Tumor Responses -- Low-Dose/Dose-Rate Apoptosis -- Low-Dose Hyper-radiosensitivity-Increased Radioresistance -- G2 Synchronization, Bystander, and Cross-Fire Effects -- Adaptive Responses -- Fractionated RNT and Hypoxia -- Future Directions -- Dosimetry: Overview on Methods -- Clinical Experience -- ¹³¹I-iodide Therapy of Differentiated Thyroid Carcinoma -- Peptide Receptor Radionuclide Therapy -- Radioimmunotherapy of Lymphoma -- Dosimetry in the Radioembolization of Liver Tumors -- Therapy of Neuroectodermal Neuroendocrine Malignancies.
Treatment of Metastatic Bone Pain.
